S. Hooshmand

O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors

Jeffrey W. Clark, J. Meyerhardt, C. Fuchs, 2008 .

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Xihong Lin, D. Christiani, Z. Qian, 2013, Endocrine-related cancer.

Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.

Xihong Lin, D. Christiani, S. Ogino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

D. Christiani, R. Heist, J. Wain, 2009, Pharmacogenetics and genomics.

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

J. Meyerhardt, M. Tzardi, S. Ogino, 2009, British Journal of Cancer.

A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.

Manal M. Hassan, R. Sackler, J. Hoh, 2011, Endocrine-related cancer.

Somatic mutation of CDKN1B in small intestine neuroendocrine tumors

Trevor J Pugh, J. Grimsby, N. Lennon, 2013, Nature Genetics.

Preferential amplification of apoptotic DNA from plasma: potential for enhancing detection of minor DNA alterations in circulating DNA.

C. Hader, H. Mamon, G. Makrigiorgos, 2008, Clinical chemistry.

Genetic associations with sporadic neuroendocrine tumor risk.

Xihong Lin, J. Paulus, D. Christiani, 2011, Carcinogenesis.

Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs).

Xihong Lin, D. Christiani, M. Kulke, 2010 .

Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies

D. Zurakowski, M. Moses, J. Wischhusen, 2014, British Journal of Cancer.